PT-141 / Bremelanotide
MC4R agonist in the central nervous system associated with sexual desire and arousal, with clinical data in HSDD and earlier work in erectile dysfunction.
View medication pageTherapy Hub
Sexual Health
Sexual health therapies in this hub are organized around desire, arousal, and central nervous system signaling. These compounds belong here because the clinical and mechanistic literature links melanocortin or oxytocin pathways to sexual desire, arousal, bonding, or aspects of sexual function, although the quality and consistency of evidence differ across products and populations.
Available Medications
Each medication below is grouped here because its mechanism, clinical use, or published literature helps explain why it fits this therapy category.
Oxytocin
Studied for effects on desire, arousal, lubrication, bonding, and sexual satisfaction, though findings are mixed across settings.
View medication pageMore Medications Available
This is not a comprehensive list of our available medications. We have what you need.
Contact us for moreEstradiol Vaginal Cream 0.03%
Localized estradiol support for GSM symptoms, tissue comfort, and dyspareunia-related care.
View medication page
Estradiol Vaginal Tablets / Suppository
Low-dose local estradiol support for vaginal tissue health and comfort.
View medication page
Injectable Testosterone Cypionate
Individualized testosterone protocols used with careful monitoring in selected sexual health plans.
View medication page
Transdermal Testosterone Cream
Daily transdermal testosterone support used selectively with monitoring in sexual health care.
View medication page
References
Studies, data, and supporting evidence
These references support the positioning statements used on this therapy hub. They are intended as educational source material for patients and prescribers, not as a substitute for individualized medical judgment.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder
The phase 3 RECONNECT trials showed bremelanotide improved sexual desire and reduced related distress in premenopausal women with HSDD.
Full Text →The 2020 Genitourinary Syndrome of Menopause Position Statement of The North American Menopause Society
NAMS supports low-dose vaginal estrogen as an effective option for moderate to severe GSM, including dyspareunia and vaginal dryness, when nonprescription measures are insufficient.
PubMed →The REJOICE Trial: Vaginal Estradiol Soft-gel Capsule for Symptomatic Vulvar and Vaginal Atrophy
This phase 3 trial found vaginal estradiol improved dyspareunia, vaginal pH, and epithelial markers, supporting local estradiol therapy for GSM-related sexual discomfort.
PubMed →Global Consensus Position Statement on the Use of Testosterone Therapy for Women
The consensus concludes that the only evidence-based indication for testosterone in women is HSDD, which supports careful sexual-health positioning while avoiding broader unsupported claims.
Full Text →ISSWSH Clinical Practice Guideline for the Use of Systemic Testosterone for HSDD in Women
ISSWSH offers detailed clinical guidance for systemic testosterone therapy in women with HSDD, including monitoring and use within physiologic ranges.
PubMed →